For more than 120 years, Roche has been committed to improving lives.  The long term thinking of our founders has allowed us to stay true to this vision and shapes the way we make a difference in the lives of millions of patients around the world. 

Headquartered in Basel, Switzerland, we are a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics, our two core business areas. 

We are the world’s largest biopharmaceutical company, with truly differentiated medicines in cancer immunology, infectious diseases, ophthalmology and neuroscience. 

Thirty-two medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them antibiotics, anti-malarials and chemotherapy. 

Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner diabetes management.  For more information visit: www.roche-australia.com 

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros. For more information, go to www.bayer.com.

Alcon: Dedicated to helping people see brilliantly

Alcon is the global leader in eye care with over 75 years dedicated to helping people see brilliantly. Alcon offers a wide spectrum of eye care products in surgical, pharmaceutical and vision care.
We offer a complete line of ophthalmic surgical products, enabling surgeons to achieve optimal results for their patients. Our surgical portfolio includes technologies and devices for cataract, vitreoretinal, refractive surgery, as well as advanced technology intraocular lenses to treat cataracts and refractive errors, like presbyopia and astigmatism. Other implantables include Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device. We also provide advanced viscoelastics, surgical solutions, visualisation, Custom Paks®, and other disposable products for cataract and vitreoretinal surgery.
Alcon has a strong commitment to its partnership with eye care professionals and humanitarian organisations locally and internationally.   Alcon is also proud to have recently launched its Reflect Reconciliation Action Plan with a vision to improve the quality of life of Aboriginal and Torres Strait Islander peoples across Australia by significantly improving eye health equity and creating employment, education, and business opportunities for First Nations peoples.

©2026 Alcon Laboratories Pty Ltd. AUS: 1800 224 153; Auckland NZ: 0800 101 106. ANZ-HDM-2400026

Since the exciting news of Lumibird’s acquisition and merger of Ellex and Quantel Medical, our global focus continues to remain committed to providing innovative world-class ophthalmic technologies, dedicated to the diagnosis and treatment of leading causes of blindness worldwide: glaucoma, cataracts, AMD and diabetic retinopathy. 

Glaukos – Transforming Vision. 

Glaukos is an ophthalmic device and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.  

Innovation is at the core of everything we do. Our mission is to truly transform vision by pioneering novel, dropless platforms that can meaningfully advance the standard of care and improve outcomes for patients suffering from sight-threatening chronic eye diseases. Our mantra “We’ll Go First” embodies our commitment and determination to push the limits of science and technology to disrupt and improve the legacy treatment paradigms in glaucoma, corneal disorders and retinal diseases.  

We were the first company to bring to market Micro-Invasive Glaucoma Surgery (MIGS), revolutionising the treatment and management of glaucoma. To date over 1M iStents have been implanted worldwide. 

Avant is a member-owned organisation that protects and supports doctors throughout their careers and lives. Avant medical indemnity insurance protects over half of doctors in Australia. A broad range of other products and services include private health and general insurances, practice technology solutions and supplies, and specialist lending services. Speak with Tasmanian State Manager Ngaire Burgess for more information on any of Avant’s many products and services for Doctors, by Doctors.

Across Australia, thousands of people experience permanent changes in vision each year. While their medical eye care is essential, many patients continue to struggle with everyday tasks, digital access, confidence, and emotional wellbeing. This gap between clinical treatment and day-to-day life is where SeeWay provides vital support. 

SeeWay is a national, free service that complements ophthalmic and optometric care by helping people adapt to life with low vision. We offer personalised digital skills training, access to a professional counselling service, curated resources, and connections to practical supports – ensuring patients have guidance not only in the consulting room, but in the real-world environments where vision loss is most felt. 

Developed with input from clinicians, researchers, and people with lived experience, SeeWay equips patients to remain independent, informed, and connected to what matters most to them. Early, holistic intervention while a person still has some usable vision has been shown to improve functional and emotional outcomes, and adjustment to daily life.  

With more than 70,000 Australians living with moderate low vision who do not qualify for funded supports, SeeWay helps bridge the gap, providing accessible, lifestyle support that improves lifestyle outcomes for patients and complements the care delivered by eye health professionals. 

Apellis is an international biopharmaceutical company, headquartered in the United States and established in Australia in 2020. Our company is committed to leading the development of therapies that target the complement cascade of the immune system, leveraging courageous science and compassion to deliver life-changing medicines for patients. 

Apellis Australia Pty Ltd 

www.apellis.com.au 

1300 833 138 

medical.anz@apellis.com  

The Carl Zeiss Group is a leading group of companies operating worldwide in the optical and opto-electronic industries.  Headquartered in Oberkochen and Jena, Germany, Carl Zeiss is represented in more than 50 countries 
  
ZEISS has pioneered numerous ground-breaking ophthalmological technologies and leads the way in multiple areas in the clinic and theatre environment.

Bausch+Lomb is the company solely dedicated to protecting and enhancing the gift of sight for millions of people around the world.  From the moment of birth, through to every phase of life.  

For nearly two centuries, Bausch+Lomb has been at the forefront of optical innovation They offer the worlds widest and finest range of eye health products including contact lenses and lens care products, ophthalmic pharmaceuticals, intraocular lenses and an extensive range of ophthalmic surgical devices and instruments. 

A recent innovation includes the enVista Envy IOL, a diffractive, hydrophobic acrylic lens built on the trusted enVista platform. This lens has an enviable tolerance to dysphotopsias, 4D of continuous vision, outstanding performance in all lighting conditions and has toric powers down to 0.9D. 

Another Bausch and Lomb exclusive is the SeeLuma 3D visualisation system. SeeLuma offers the only fully digital surgical system. This means the option of no more binoculars, sharing images with all staff in the theatre and elsewhere in real time, tools for teaching, a range of digital filters and perhaps most importantly, improved ergonomics. 

The Stellaris PC platform provides a high-performance, feature-rich, combined experience that leverages Bausch + Lomb’s legacy of vitreoretinal surgical innovation with the demonstrated excellence of the Stellaris phacoemulsification platform. Stellaris PC Next Generation with integrated green laser allows surgeons to have true “procedural choice” by providing the most advanced technology for both vitreoretinal and cataract surgery in a single system.  

Bausch+Lomb offers a wide range of microsurgical instruments for ophthalmology. To help surgeons achieve the best outcomes using their preferred techniques, Bausch+Lomb Storz® Ophthalmic Instruments offer a very wide range of leading designs with trusted the quality, earned over 120 years of collaborating with surgeons. 

For more information please contact your Bausch+Lomb Territory Manager, or Bausch+Lomb Customer Service at ausorders@bausch.com or on 1800251150. 

For more than 30 years, BOQ Specialist have provided medical professionals with specialised banking solutions to help them achieve their professional and personal ambitions.  

Whether you require personal banking products or business solutions for your practice, there’s a specialist waiting to help. For more information call 1300 160 160 or visit www.boqspecialist.com.au/medical